Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
| ▸ | EIF4E | P06730 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120666 | 0.88 | GPR119 (0.59) | GPR119MKNK2EIF4EMKNK1LRRK2 | |
| SCHEMBL12319936 | 0.87 | GPR119 (0.58) | GPR119LRRK2 | |
| SCHEMBL10120508 | 0.87 | GPR119 (0.51) | GPR119MKNK2EIF4EMKNK1LRRK2 | |
| SCHEMBL10120456 | 0.86 | GPR119 (0.55) | GPR119MKNK2EIF4EMKNK1 | |
| SCHEMBL10120454 | 0.85 | GPR119 (0.47) | GPR119MKNK2EIF4EMKNK1LRRK2 | |
| SCHEMBL10134279 | 0.82 | GPR119 (0.48) | GPR119MKNK2EIF4EMKNK1LRRK2 | |
| SCHEMBL15381348 | 0.82 | GPR119 (0.52) | GPR119MKNK2EIF4EMKNK1LRRK2 | |
| SCHEMBL10121102 | 0.80 | GPR119 (0.50) | GPR119 | |
| SCHEMBL10116444 | 0.80 | GPR119 (0.37) | GPR119MKNK2MKNK1 | |
| SCHEMBL10134325 | 0.79 | AR (0.50) | GPR119MKNK2EIF4EMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | GPR119 1/4885MKNK2 1402/4885EIF4E 2584/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | GPR119 1/4885MKNK2 1880/4885EIF4E 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.